AMIH Majority Owned Subsidiary, EPIQ Scripts, Obtains Controlled Substance Registration from the U.S. Department of Justice & Drug Enforcement Administration (DEA)
American International Holdings Corp. (AMIH) announced that its subsidiary, EPIQ Scripts, received a controlled substance registration from the DEA, allowing it to operate in nearly 30 U.S. States. EPIQ Scripts has also applied for various national accreditations to enhance its services in the telemedicine market. The company aims to compete with established online pharmacies, targeting significant growth in the sector. However, there is no guarantee that the pending applications for licenses and accreditations will be approved in a timely manner.
- EPIQ Scripts obtained a DEA License allowing operation in almost 30 U.S. States.
- Applications submitted for national accreditations may increase EPIQ Scripts' credibility and market access.
- The company aims to compete with major players like TruePill, indicating potential for growth.
- No assurance of timely approval for accreditation applications.
- Dependence on regulatory approvals may delay operations.
EPIQ Scripts has also submitted applications for various nationally recognized accreditation agencies and associations
Dallas, Texas, Dec. 01, 2022 (GLOBE NEWSWIRE) -- American International Holdings Corp. (OTCQB: AMIH), (“AMIH” or the “Company”), a diversified holding company that develops, acquires, and operates technology-based health and wellness companies, is pleased to announce that its majority owned subsidiary, EPIQ Scripts, LLC (“EPIQ Scripts”), has been granted a controlled substance registration (CSR) from the U.S. Department of Justice & Drug Enforcement Administration (“DEA License”).
In addition to obtaining its DEA License, EPIQ Scripts has submitted applications with various national accreditation associations including the Utilization Review Accreditation Commission (URAC) for both mail order and specialty pharmacy accreditations, LegitScript for its online healthcare merchant certification, the Accreditation Commission for Health Care (ACHC) and Pharmacy Compounding Accreditation Board (PCAB) for non-sterile pharmacy compounding and has become a member of the National Council for Prescription Drug Programs (NCPDP) and the American Telemedicine Association. We can provide no assurance that such licenses and accreditations applied for will be approved on a timely basis, if at all.
“Our goal is to eventually position EPIQ Scripts to compete with TruePill - the online pharmacy most recently valued at
About American International Holdings Corp.
American International Holdings Corp. (OTCQB:AMIH) is an investor, developer and asset manager diversified across the healthcare supply chain. Today the AMIH portfolio encompasses telemedicine and other virtual health platforms, subscriber based primary care and concierge medicine plans, and an online digital mail order pharmacy. AMIH provides its various services through direct-to-consumer and business-to-business distribution channels. AMIH’s focus is on developing, acquiring, and bringing to market technologies and solutions that advance the quality of life for the global community.
About EPIQ Scripts:
EPIQ Scripts is an online mail-order specialty compounding pharmacy based in the State of Texas with its focus on servicing and supporting direct-to-consumer telemedicine companies. EPIQ Scripts is a member of the American Telemedicine Association and is currently licensed to operate and fulfill prescriptions in the following 29 U.S. States: Alaska, Arkansas, Colorado, Delaware, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kansas, Maryland, Massachusetts, Mississippi, Missouri, Nebraska, New Jersey, New Mexico, New York, Oklahoma, Oregon, Pennsylvania, Rhode Island, Texas, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management’s view of the Company’s future expectations, plans and prospects, within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management's current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” and other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, operations, expansion, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company's actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to the proposed operations of EPIQ Scripts, the ability of EPIQ Scripts’ to obtain and maintain licenses and accreditations, the timing of such licenses and accreditations, and limitations on its operations if such licenses and accreditations are not in place, and future projected revenues, customers, and results of operations of EPIQ Scripts; economic conditions, changes in the laws or regulations, demand for products and services of the Company; our limited operating history; our need for additional funding to support our operations, repay debt and expand our operations; the effects of COVID-19 on our operations and prospects, and the future effects of COVID-19 on us and our operations; impairments we may be required to assess in connection with our assets and goodwill; risks associated with our prior launch of a telehealth platform, including liability in connection therewith, funding needed to support such operations and other risks associated with the operations of the telehealth platform; disruptions to our operations or liabilities associated with future acquisitions; our ability to continue as a going concern; our dependence on our Chief Executive Officer, Jacob D. Cohen, and related party transactions affecting the Company; Mr. Cohen’s voting control over the Company; competition we face; our ability to maintain our varied operations, and service our indebtedness; material weaknesses in our controls and procedures; our ability to obtain and maintain adequate insurance; legal challenges and litigation; risks associated with national and global recessions and inflation; liability associated with our contracting operations; the terms of Mr. Cohen’s employment agreement; dilution caused by the conversion of outstanding convertible notes, exercise of outstanding warrants, and future fund-raising activities; anti-dilution and favored nation provisions of our outstanding convertible notes and warrants; the price of, volatility in, and lack of robust trading market for, our common stock; global economic conditions; geopolitical events and regulatory changes; access to additional financing, and the potential lack of such financing; and the Company’s ability to raise funding in the future and the terms of such funding; and the effect of rising interest rates and inflation, and economic downturns and recessions; and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. These risk factors and others are included from time to time in filings made by the Company with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Investor Relations Contact
Frank Benedetto
(619) 915-9422
FAQ
What is the significance of the DEA License obtained by AMIH's EPIQ Scripts?
What accreditations has EPIQ Scripts applied for?
How does AMIH plan to compete with TruePill?
Is there any risk associated with EPIQ Scripts' accreditation applications?
